• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W.L. GORE & ASSOCIATES GORE VIABAHN® ENDOPROSTHESIS; STENT, SUPERFICIAL FEMORAL ARTERY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W.L. GORE & ASSOCIATES GORE VIABAHN® ENDOPROSTHESIS; STENT, SUPERFICIAL FEMORAL ARTERY Back to Search Results
Catalog Number VBH090502A
Device Problems Sticking (1597); Malposition of Device (2616); Activation, Positioning or Separation Problem (2906)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 01/26/2017
Event Type  Injury  
Manufacturer Narrative
Udi number: (b)(4).Review of device manufacturing record history confirmed device met pre-release specifications.The device was not returned.Therefore, direct product analysis was not possible.Ifu method state, prior to implantation of the gore® viabahn® endoprosthesis with heparin bioactive surface, the physician should refer to the sizing table (table 1) and read the directions for use.Sizing table recommendation is to use 0.035" guidewire diameter.Ifu warnings state: special care should be taken to ensure that the appropriate size endoprosthesis, compatible sheath and guidewire are selected prior to introduction.Do not attempt to deploy the endoprosthesis or manipulate the delivery system without an appropriately sized guidewire (table 1) and fluoroscopic guidance.
 
Event Description
Patient presented for an arteriovenous access revision in the upper arm due to a fistula and stenosis.The intended treatment site had an existing bare metal stent (manufacturer unknown).It was reported the physician advanced the gore® viabahn® endoprosthesis without the aid of a sheath, over a.018 guidewire.The gore® viabahn® endoprosthesis reached the target site and the device partially deployed when the deployment line became stuck.The viabahn catheter was pushed forward and the gore® viabahn® endoprosthesis was able to be deployed some more before getting stuck again.The physician manipulated the catheter again in order to release the rest of the constrained gore® viabahn® endoprosthesis.However, the gore® viabahn® endoprosthesis moved more centrally, beyond the targeted landing zone.In order to remove the partially expanded gore® viabahn® endoprosthesis, the axillary vein was cut and the device was removed, along with the still attached deployment line.The vein was surgically repaired and the patient is recovering well.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE VIABAHN® ENDOPROSTHESIS
Type of Device
STENT, SUPERFICIAL FEMORAL ARTERY
Manufacturer (Section D)
W.L. GORE & ASSOCIATES
flagstaff AZ
Manufacturer (Section G)
MEDICAL ECHO RIDGE B/P
3250 w. kiltie lane
flagstaff AZ 86005
Manufacturer Contact
genevieve begay
1500 n. 4th street
flagstaff, AZ 
9285263030
MDR Report Key6314517
MDR Text Key66914659
Report Number2017233-2017-00072
Device Sequence Number1
Product Code NIP
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P040037
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative
Reporter Occupation Physician
Type of Report Initial
Report Date 01/27/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/09/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date08/31/2018
Device Catalogue NumberVBH090502A
Device Lot Number14401412
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured09/01/2015
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
.018 GUIDEWIRE
Patient Outcome(s) Required Intervention;
Patient Age59 YR
-
-